Radioimmunotherapy (RIT) uses monoclonal antibodies to deliver radionuclides to cancer cells, but minimizing radiation to healthy tissues remains challenging Here, Puchol Tarazona and colleagues present PreTarg-it, a novel pretargeted RIT approach featuring a two-step regimen for optimized radioactivity delivery. Their pilot study combines the bispecific antibody ON105, which targets oxidized macrophage migration inhibitory factor (oxMIF) and histamine-succinyl-glycyl (HSG), with the 177Lu-labeled DOTA-di-HSG hapten (IMP288). This approach led to significant tumor regression and 100% survival in CT26 colorectal and CFPAC-1 pancreatic cancer mouse models, showing promise for treating challenging solid tumors like pancreatic cancer and late-stage malignancies.

Combining immunotherapy with other cancer drugs can improve outcomes in patients with metastatic disease. Here Dolan and colleagues identify a senescence-mimicking (“senomimetic”) side-effect of antiangiogenic tyrosine kinase inhibitors (TKIs) that can enhance IFN signaling in tumor cells via activation of the STimulator of INterferon Gene (STING) pathway. These STING-activating effects “primed” tumors for...

You do not currently have access to this content.